Compare SXI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXI | ACAD |
|---|---|---|
| Founded | 1955 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.3B |
| IPO Year | 1994 | 2000 |
| Metric | SXI | ACAD |
|---|---|---|
| Price | $303.80 | $24.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | ★ $289.67 | $30.55 |
| AVG Volume (30 Days) | 201.7K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 6.98 | 0.02 |
| Revenue | $604,535,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $14.87 | $18.80 |
| Revenue Next Year | $6.07 | $11.70 |
| P/E Ratio | ★ $44.21 | $1,241.50 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $163.30 | $19.69 |
| 52 Week High | $363.89 | $28.35 |
| Indicator | SXI | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 51.72 |
| Support Level | $297.07 | $20.56 |
| Resistance Level | $363.89 | $25.36 |
| Average True Range (ATR) | 10.58 | 0.76 |
| MACD | -2.40 | -0.26 |
| Stochastic Oscillator | 38.69 | 23.84 |
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.